Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests
07 October 2020
BioCentury
Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.
People
Related News
27 December 2024
In the News
Foley Partners with Utah Business to Host Energy Sector Roundtable Discussion
Foley & Lardner LLP partnered with Utah Business to host a roundtable discussion featuring several of Utah's leading figures in the energy sector.
24 December 2024
In the News
Steven Barth on 2024's Dealmaking Challenges – 'Tradeoff between price and deal certainty had never been higher'
Foley & Lardner LLP partner Steven Barth discussed challenges dealmakers faced this year in the PitchBook article, "M&A 2024: Rebounding from rates and regulations."
24 December 2024
In the News
Alejandro Gomez-Strozzi Discusses Proposed Mexican Constitutional Amendment on GM Corn
Foley & Lardner LLP partner Alejandro Gómez-Strozzi shared insight in the Reforma article, "Se debe acatar panel de maíz; no se puede 'darle la vuelta'" on Mexican President Claudia Sheinbaum's decision to propose a constitutional amendment banning the planting of genetically modified (GM) corn in the country